AD-102

**AD-102** is Addpharma's oral fixed-dose combination of raloxifene and cholecalciferol developed for postmenopausal osteoporosis. The product combines raloxifene, a selective estrogen receptor modulator that produces estrogenic effects in bone and reduces bone resorption, with cholecalciferol, a vitamin D3 prohormone that is converted to calcitriol and supports calcium and phosphate homeostasis through vitamin D receptor signaling. In the completed randomized crossover bioequivalence study NCT03824171, AD-102 was administered as raloxifene 45 mg plus cholecalciferol 800 IU tablets and compared with raloxifene 60 mg plus cholecalciferol 800 IU. Addpharma reported bioequivalence confirmation in 2020 and a marketing-authorization filing for postmenopausal osteoporosis in November 2020. ([ctv.veeva.com](https://ctv.veeva.com/study/evaluating-the-pharmacokinetic-characteristics-of-ad-102-in-healthy-volunteers))